Shanghai Fosun Pharmaceutical Group Co Ltd (600196) - Net Assets

Latest as of December 2025: CN¥62.49 Billion CNY ≈ $9.14 Billion USD

Based on the latest financial reports, Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has net assets worth CN¥62.49 Billion CNY (≈ $9.14 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥120.47 Billion ≈ $17.63 Billion USD) and total liabilities (CN¥57.97 Billion ≈ $8.48 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600196 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥62.49 Billion
% of Total Assets 51.88%
Annual Growth Rate 29.69%
5-Year Change 29.18%
10-Year Change 147.5%
Growth Volatility 73.57

Shanghai Fosun Pharmaceutical Group Co Ltd - Net Assets Trend (1995–2025)

This chart illustrates how Shanghai Fosun Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Shanghai Fosun Pharmaceutical Group Co L (600196) total assets for the complete picture of this company's asset base.

Annual Net Assets for Shanghai Fosun Pharmaceutical Group Co Ltd (1995–2025)

The table below shows the annual net assets of Shanghai Fosun Pharmaceutical Group Co Ltd from 1995 to 2025. For live valuation and market cap data, see 600196 market cap.

Year Net Assets Change
2025-12-31 CN¥62.49 Billion
≈ $9.14 Billion		 +4.27%
2024-12-31 CN¥59.93 Billion
≈ $8.77 Billion		 +5.86%
2023-12-31 CN¥56.62 Billion
≈ $8.28 Billion		 +4.63%
2022-12-31 CN¥54.11 Billion
≈ $7.92 Billion		 +11.85%
2021-12-31 CN¥48.38 Billion
≈ $7.08 Billion		 +5.20%
2020-12-31 CN¥45.98 Billion
≈ $6.73 Billion		 +17.29%
2019-12-31 CN¥39.20 Billion
≈ $5.74 Billion		 +16.70%
2018-12-31 CN¥33.59 Billion
≈ $4.92 Billion		 +12.95%
2017-12-31 CN¥29.74 Billion
≈ $4.35 Billion		 +17.79%
2016-12-31 CN¥25.25 Billion
≈ $3.69 Billion		 +22.16%
2015-12-31 CN¥20.67 Billion
≈ $3.02 Billion		 +8.20%
2014-12-31 CN¥19.10 Billion
≈ $2.80 Billion		 +8.14%
2013-12-31 CN¥17.66 Billion
≈ $2.58 Billion		 +15.42%
2012-12-31 CN¥15.30 Billion
≈ $2.24 Billion		 +34.60%
2011-12-31 CN¥11.37 Billion
≈ $1.66 Billion		 +21.05%
2010-12-31 CN¥9.39 Billion
≈ $1.37 Billion		 +35.12%
2009-12-31 CN¥6.95 Billion
≈ $1.02 Billion		 +56.37%
2008-12-31 CN¥4.45 Billion
≈ $650.58 Million		 +3.00%
2007-12-31 CN¥4.32 Billion
≈ $631.62 Million		 +18.30%
2006-12-31 CN¥3.65 Billion
≈ $533.90 Million		 +26.90%
2005-12-31 CN¥2.88 Billion
≈ $420.71 Million		 +2.18%
2004-12-31 CN¥2.81 Billion
≈ $411.75 Million		 +39.51%
2003-12-31 CN¥2.02 Billion
≈ $295.14 Million		 +20.53%
2002-12-31 CN¥1.67 Billion
≈ $244.87 Million		 +26.52%
2001-12-31 CN¥1.32 Billion
≈ $193.54 Million		 +8.55%
2000-12-31 CN¥1.22 Billion
≈ $178.30 Million		 +85.44%
1999-12-31 CN¥657.08 Million
≈ $96.15 Million		 +23.80%
1998-12-31 CN¥530.77 Million
≈ $77.67 Million		 +300.05%
1997-12-31 CN¥132.68 Million
≈ $19.41 Million		 +314.91%
1996-12-31 CN¥31.98 Million
≈ $4.68 Million		 +24.91%
1995-12-31 CN¥25.60 Million
≈ $3.75 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Fosun Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1010853.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥29.80 Billion 61.14%
Common Stock CN¥2.67 Billion 5.48%
Other Comprehensive Income CN¥714.03 Million 1.46%
Other Components CN¥15.55 Billion 31.91%
Total Equity CN¥48.74 Billion 100.00%

Shanghai Fosun Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Fosun Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
Beacon Roofing Supply Inc
NASDAQ:BECN
 $7.72 Billion
One 97 Communications Limited
NSE:PAYTM
 $7.72 Billion
Nemetschek AG O.N.
XETRA:NEM
 $7.73 Billion
TURK HA.YO.UNS.ADR 10 TN1
F:TU5A
 $7.74 Billion
Hoshine Silicon Ind Co Ltd
SHG:603260
 $7.72 Billion
Chang Hwa Commercial Bank Ltd
TW:2801
 $7.71 Billion
Tripod Technology Corp
TW:3044
 $7.71 Billion
Indutrade AB
ST:INDT
 $7.71 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Fosun Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 47,261,107,000 to 48,741,507,000, a change of 1,480,400,000 (3.1%).
  • Net income of 3,370,562,000 contributed positively to equity growth.
  • Dividend payments of 844,702,310 reduced retained earnings.
  • Share repurchases of 411,788,500 reduced equity.
  • Other comprehensive income decreased equity by 792,007,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥3.37 Billion +6.92%
Dividends Paid CN¥844.70 Million -1.73%
Share Repurchases CN¥411.79 Million -0.84%
Other Comprehensive Income CN¥-792.01 Million -1.62%
Other Changes CN¥158.34 Million +0.32%
Total Change CN¥- 3.13%

Book Value vs Market Value Analysis

This analysis compares Shanghai Fosun Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.35x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 1709.69x to 1.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.01 CN¥24.89 x
1996-12-31 CN¥0.02 CN¥24.89 x
1997-12-31 CN¥0.06 CN¥24.89 x
1998-12-31 CN¥0.30 CN¥24.89 x
1999-12-31 CN¥0.34 CN¥24.89 x
2000-12-31 CN¥0.65 CN¥24.89 x
2001-12-31 CN¥0.72 CN¥24.89 x
2002-12-31 CN¥0.80 CN¥24.89 x
2003-12-31 CN¥0.97 CN¥24.89 x
2004-12-31 CN¥1.31 CN¥24.89 x
2005-12-31 CN¥1.36 CN¥24.89 x
2006-12-31 CN¥1.76 CN¥24.89 x
2007-12-31 CN¥2.10 CN¥24.89 x
2008-12-31 CN¥2.17 CN¥24.89 x
2009-12-31 CN¥3.49 CN¥24.89 x
2010-12-31 CN¥4.49 CN¥24.89 x
2011-12-31 CN¥5.11 CN¥24.89 x
2012-12-31 CN¥6.94 CN¥24.89 x
2013-12-31 CN¥6.81 CN¥24.89 x
2014-12-31 CN¥7.26 CN¥24.89 x
2015-12-31 CN¥7.83 CN¥24.89 x
2016-12-31 CN¥9.49 CN¥24.89 x
2017-12-31 CN¥10.29 CN¥24.89 x
2018-12-31 CN¥11.06 CN¥24.89 x
2019-12-31 CN¥12.44 CN¥24.89 x
2020-12-31 CN¥14.44 CN¥24.89 x
2021-12-31 CN¥15.29 CN¥24.89 x
2022-12-31 CN¥17.10 CN¥24.89 x
2023-12-31 CN¥17.04 CN¥24.89 x
2024-12-31 CN¥17.74 CN¥24.89 x
2025-12-31 CN¥18.42 CN¥24.89 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Fosun Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 6.92%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.12%
  • • Asset Turnover: 0.34x
  • • Equity Multiplier: 2.47x
  • Recent ROE (6.92%) is below the historical average (13.49%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 23.35% 9.25% 0.61x 4.17x CN¥3.42 Million
1996 19.95% 6.88% 0.83x 3.48x CN¥3.18 Million
1997 39.35% 20.82% 0.66x 2.85x CN¥29.56 Million
1998 12.28% 18.72% 0.53x 1.25x CN¥11.81 Million
1999 15.25% 20.83% 0.52x 1.42x CN¥31.71 Million
2000 11.22% 22.67% 0.36x 1.37x CN¥13.96 Million
2001 10.72% 18.62% 0.33x 1.75x CN¥9.12 Million
2002 10.44% 14.27% 0.33x 2.23x CN¥6.26 Million
2003 15.51% 12.24% 0.51x 2.48x CN¥93.60 Million
2004 9.35% 8.94% 0.47x 2.24x CN¥-15.08 Million
2005 6.65% 5.32% 0.53x 2.37x CN¥-80.06 Million
2006 8.39% 6.35% 0.62x 2.15x CN¥-49.86 Million
2007 16.16% 16.94% 0.50x 1.92x CN¥238.55 Million
2008 17.23% 18.31% 0.50x 1.88x CN¥289.97 Million
2009 38.57% 64.88% 0.33x 1.78x CN¥1.85 Billion
2010 10.25% 18.96% 0.27x 2.00x CN¥21.35 Million
2011 11.93% 17.97% 0.29x 2.28x CN¥188.42 Million
2012 11.53% 21.30% 0.29x 1.88x CN¥208.04 Million
2013 10.32% 15.83% 0.34x 1.92x CN¥49.34 Million
2014 12.67% 17.57% 0.34x 2.12x CN¥445.38 Million
2015 13.53% 19.51% 0.33x 2.10x CN¥641.94 Million
2016 12.64% 19.18% 0.33x 1.97x CN¥586.82 Million
2017 12.34% 16.86% 0.30x 2.45x CN¥591.81 Million
2018 9.68% 10.87% 0.35x 2.52x CN¥-89.85 Million
2019 10.42% 11.62% 0.38x 2.39x CN¥132.81 Million
2020 9.90% 12.09% 0.36x 2.26x CN¥-36.74 Million
2021 12.07% 12.12% 0.42x 2.38x CN¥809.52 Million
2022 8.37% 8.49% 0.41x 2.40x CN¥-727.44 Million
2023 5.22% 5.76% 0.36x 2.48x CN¥-2.18 Billion
2024 5.86% 6.74% 0.35x 2.49x CN¥-1.96 Billion
2025 6.92% 8.12% 0.34x 2.47x CN¥-1.50 Billion

Industry Comparison

This section compares Shanghai Fosun Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,724,724,027
  • Average return on equity (ROE) among peers: 8.55%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) CN¥62.49 Billion 23.35% 0.93x $7.72 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $780.79 Million 3.11% 2.56x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.05 Billion 2.59% 0.88x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $5.18 Billion
Livzon Pharmaceutical Group Inc (000513) $623.47 Million 16.22% 0.40x $2.81 Billion
Wedge Industrial Co Ltd (000534) $654.70 Million 1.92% 0.87x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $473.92 Million 15.85% 0.78x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $275.57 Million 17.28% 1.12x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $702.49 Million 2.58% 0.66x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $999.14 Million 3.56% 1.59x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.35 Billion 7.34% 0.44x $3.30 Billion

About Shanghai Fosun Pharmaceutical Group Co Ltd

SHG:600196 China Drug Manufacturers - Specialty & Generic
Market Cap
$7.72 Billion
CN¥52.73 Billion CNY
Market Cap Rank
#2680 Global
#336 in China
Share Price
CN¥24.89
Change (1 day)
-1.54%
52-Week Range
CN¥23.51 - CN¥32.15
All Time High
CN¥85.06
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more